Evidence map›Paper›PMID 38867804›Full record

ArticleAsian journal of pharmaceutical sciences2024

Advancing ophthalmic delivery of flurbiprofen via synergistic chiral resolution and ion-pairing strategies.

Zhining Ma, Yuequan Wang, Huiyang He, Tong Liu, Qikun Jiang, Xiaohong Hou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhining MaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yuequan WangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Huiyang HeWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Tong LiuLiaoning Provincial Institute of Drug Inspection and Testing, Shenyang 110036, China.
Qikun JiangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xiaohong HouSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flurbiprofen (FB), a nonsteroidal anti-inflammatory drug, is widely employed in treating ocular inflammation owing to its remarkable anti-inflammatory effects. However, the racemic nature of its commercially available formulation (Ocufen®) limits the full potential of its therapeutic activity, as the (

Indexed as

Anti-inflammatoryChiral resolutionFlurbiprofenIon-pairingOphthalmic delivery

Identifiers

PMID38867804
PMCPMC11165342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.